A big study published in 2016, called the PRECISION trial, found that people with arthritis who take the anti-inflammatory drug ibuprofen are more likely to develop cardiovascular problems than those using celecoxib – and now researchers think they know why. Ibuprofen raises blood pressure, according to new findings presented recently at the annual meeting of the European Society of Cardiology in Barcelona.
The number of biosimilars approved by the Food and Drug Administration (FDA) continues to grow in the United States, and they are slowly becoming available to consumers.
In late August, the FDA approved Cyltezo (adalimumab-adbm), a second biosimilar to Humira (adalimumab). But like the first biosimilar, Amjevita (adalimumab-atto), which was approved in September 2016, it is not yet available to U.S. consumers because of pending patent litigation with AbbVie, the manufacturer of Humira.
“You are what you eat” is a phrase we often hear. But how true is it? Dr. Richard F. Loeser, Jr. and his research team are looking at the role of diet in their Arthritis Foundation-funded project “The Role of the Microbiome in Metabolic Osteoarthritis (OA)”.
Different factors play into why a person develops OA, including aging, injury, and being overweight. Diet plays an important role. What you eat can help influence what bacteria (or microbiota) live in your digestive track (gut). This, in turn, can influence what chemicals are released into your body. A healthy gut generally has a more diverse collection of helpful microbiota, while a microbial imbalance can lead to disease.
If you’ve been diagnosed with mild to moderate fibromyalgia, exercise and other non-drug therapies should be your first line of treatment, according to the European League Against Rheumatism (EULAR), an international group of health professionals in rheumatology. EULAR’s updated fibromyalgia treatment recommendations, published in 2016 in Annals of the Rheumatic Diseases, are similar to the 2007 version, but this time they are based on hard evidence, which was scarce 10 years ago, rather than on expert opinions.
For the updated guidelines, researchers reviewed 107 research papers. Assessing outcomes for pain, fatigue, sleep and daily functioning, they ranked their recommendations of various therapies as “strong for,” “weak for,” “weak against” and “strong against.”
“Why did my child get arthritis?” This parent-driven question is at the heart of Dr. Jim Jarvis’s juvenile idiopathic arthritis (JIA) Arthritis Foundation-funded project, “Interplay between genetics and epigenetics in polyarticular JIA”.
“This is less about an illness driven by inherited genes and more about how the environment affects gene expression,” explained Dr. Jarvis. “It’s been shown that only about 30 percent of the risk for developing JIA can be attributed to gene variations.”
At the request of the U.S. Food and Drug Administration (FDA), Endo Pharmaceuticals has removed from the market its long-acting opioid pain medication, Opana ER (oxymorphone hydrochloride extended release), which some patients with arthritis take to manage chronic pain.
Every day, scientists work toward the advancement of rheumatoid arthritis (RA)treatment. And Dr. C. Michael Stein has made an exciting new discovery that could help these advancements along and predict how specific treatments will work.
Dr. Stein is looking at small molecules that have the potential to cause big problems. His 5-year Arthritis Foundation-funded project, “Extracellular small RNAs in rheumatoid arthritis,” is looking at how small molecules of ribonucleic acid (RNA) in the blood may be markers for different diseases.
Two different medical groups have separately released recommendations for patients who have osteoporosis – or are at high risk of developing it – outlining the best evidence-based treatment practices to prevent and manage the disease.
About 1 million knee arthroscopies are performed each year in the United States, at a cost of more than $3 billion. Now, in new guidelines, an international panel of experts has strongly recommended against the surgery for nearly everyone with “degenerative knee disease.” Degenerative knee disease is another way to refer to knee osteoarthritis (OA), and includes degenerative meniscus tears, trouble with knee movement and sudden onset of pain and swelling. The guidelines were published in the journal BMJ in May.
If you suffer from rheumatoid arthritis (RA), Dr. Salah Ahmed’s research project may be just your cup of (green) tea! Dr. Ahmed’s 2014 Innovative Research Grant project, “Mechanism of Mcl-1 regulation in RA by EGCG”, looked at the effects of an anti-inflammatory molecule found in green tea (epigallocatechin-3-gallate or EGCG) on a protein (Mcl-1) found in RA joints.